Company Description
Sutro Biopharma, Inc. operates as a clinical-stage oncology company.
The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+.
Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer.
Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC.
The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Sep 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | William J. Newell J.D. |
Contact Details
Address: 111 Oyster Point Blvd. South San Francisco, California 94080 United States | |
| Phone | 650-392-8412 |
| Website | sutrobio.com |
Stock Details
| Ticker Symbol | STRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001382101 |
| CUSIP Number | 869367102 |
| ISIN Number | US8693671021 |
| Employer ID | 45-2441988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| William J. Newell J.D. | Chief Executive Officer and Director |
| Jane Chung R.Ph. | President and Chief Operating Officer |
| Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder |
| Edward C. Albini M.B.A | Chief Financial Officer and Secretary |
| Dr. Venkatesh Srinivasan Ph.d. | Chief Technical Operations Officer |
| Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer |
| David Pauling J.D., M.A. | General Counsel |
| Linda A. Fitzpatrick | Chief People and Communications Officer |
| Dr. Nicki Vasquez Ph.D. | Chief Portfolio Strategy and Alliance Officer |
| Dr. Anne Elizabeth Borgman-Hagey M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2024 | 8-K | Current Report |
| May 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 2, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 424B5 | Filing |